Project Grant R01HL173869
- This federal Project Grant award of $805,921 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to integrate multi-trait, multi-ancestry, and multi-omic data from massive global biobanks to decipher the genetic mechanisms underlying respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma. The award, with a performance period from September 2025 to June 2030, will leverage data from over 2 million participants,...
- This Project Grant award of $800,679.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support the University of Virginia's research to interrogate the pathogenesis of chronic obstructive pulmonary disease (COPD) using metabolomics and genomics data. The objective is to expand the PredixCan method to incorporate metabolomics data, creating a new tool called MetaBoxCan, in order to extract more comprehensive mechanistic information from...
- This federal Project Grant award of $140,403 from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and application of new multi-omic analytical methods to elucidate the shared and divergent biology underlying chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The 5-year research project, conducted by the Harvard T.H. Chan School of Public Health, aims to 1) map conditional...
- This $761,615 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of biological sex in the heterogeneity of Acute Respiratory Distress Syndrome (ARDS). The research team at Massachusetts General Hospital aims to determine how increased alveolar epithelial expression of Secretory Leukocyte Protease Inhibitor (SLPI) in females may increase epithelial glycocalyx resilience, leading to a...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $708,063 in funding to the University of Virginia for a research project titled "Post-Transcriptional Regulatory Networks in Chronic Obstructive Pulmonary Disease". The goal of the 5-year project is to generate RNA-binding protein (RBP) regulatory networks, identify COPD-specific changes, and characterize the functional consequences of the network changes....
- This $234,000 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by Thomas Jefferson University to characterize the expression pattern of circulating short non-coding RNAs (sncRNAs) as potential biomarkers for chronic obstructive pulmonary disease (COPD). The researchers will obtain plasma samples from the SPIROMICS study to quantify the levels of two specific sncRNAs, IMMR-Val and IMMR-His, that were previously...
- This $131,783 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will fund a study to develop and implement a protocol for biospecimen collections before and after bronchoscopic lung volume reduction (BLVR) procedures in COPD patients. The goal is to identify blood and bronchoalveolar lavage fluid biomarkers associated with COPD phenotypes...
- This Project Grant award of $258,516 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund research to better understand the role of mitochondrial-derived peptides (MDPs) in the development of chronic obstructive pulmonary disease (COPD). The University of Pittsburgh will utilize the NHLBI BIOLINCC repository to analyze plasma and lung tissue samples to characterize changes in MDPs across COPD disease severity. They will combine...
- This $171,858 Project Grant, awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports a study titled "Computed Tomography for Early Detection and Phenotyping of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease with Implications for Treatment." The study aims to: Identify and validate quantitative CT imaging features for early detection of COPD-related pulmonary hypertension (COPD-PH). Apply advanced...
- The National Heart Lung and Blood Institute (NHLBI), via the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $222,750 project grant to the University of Alabama at Birmingham (UAB) to investigate genetic factors that influence susceptibility to frequent exacerbations in African American patients with chronic obstructive pulmonary disease (COPD). The key objectives are to: 1) Examine the interaction between specific variants in immunoglobulin G (IgG) and its...
MULTI-OMIC CHARACTERIZATION OF COPD IN FEMALES - ABSTRACT COPD IS THE FOURTH LEADING CAUSE OF DEATH FOR WOMEN IN THE UNITED STATES, WHICH HAS A STRONG GENETIC BASIS. STUDIES HAVE DEMONSTRATED THE HERITABILITY OF COPD TO BE ~40%. DESPITE THE ENORMOUS BURDEN OF COPD, THERE ARE STILL NO PHARMACOLOGIC THERAPIES THAT SLOW PROGRESSION OF DISEASE OR REDUCE MORTALITY, INDICATING THE NEED FOR A BETTER UNDERSTANDING OF THE GENETIC BASIS OF THE DISEASE. NOTABLY, COPD SHOWS SEX DIFFERENCES IN DISEASE PREVALENCE, PATHOLOGY, AND SYMPTOMS. ALTHOUGH HISTORICALLY THOUGHT TO AFFECT PRIMARILY MEN, THE RISK OF COPD IN WOMEN HAS INCREASED OVER TIME DUE TO GROWING PREVALENCE OF SMOKING AND EXPOSURE TO HARMFUL POLLUTANTS. THUS, OVER THE PAST DECADE, AGE-ADJUSTED PREVALENCE OF COPD HAS BEEN CONSISTENTLY HIGHER IN WOMEN THAN IN MEN. MOREOVER, WOMEN REPORT GREATER BREATHLESSNESS AT SIMILAR DEGREES OF AIRFLOW OBSTRUCTION AND EMPHYSEMA SEVERITY, AND EXPERIENCE >25% MORE EXACERBATIONS THAN MEN. DESPITE THE SEX DIFFERENCES, MOST OMICS STUDIES OF COPD COMBINE BOTH SEXES TOGETHER AND LARGE-SCALE FEMALE SPECIFIC COPD STUDIES ARE LACKING. IN THIS APPLICATION, WE PROPOSE NOVEL APPROACHES TO CONDUCT FEMALE-SPECIFIC GWAS, BORROWING STRENGTH FROM SUMMARY STATISTICS FROM LARGE SEX-COMBINED GWAS OF COPD. WE WILL ALSO GENERATE SINGLE CELL RNASEQ DATA FROM FEMALE LUNG AND INTEGRATE CELL TYPE SPECIFIC EQTLS WITH GWAS TO IDENTIFY RISK GENES. BESIDES, WE WILL ASSEMBLE A LARGE MULTI-ANCESTRY PLASMA PROTEOMICS DATASET, GENERATE FEMALE SPECIFIC PQTLS, AND USE THEM TO IDENTIFY COPD BIOMARKERS. RESULTS FROM THIS STUDY WILL BRING NOVEL INSIGHTS INTO THE MECHANISMS OF COPD IN FEMALES AND IDENTIFY PROTEIN BIOMARKERS TO AID IN THE DIAGNOSIS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $552.0k | 7/17/25 | ||
| Not listed | $572.1k | 7/25/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
UVAHL173869S | Rector & Visitors Of The University Of Virginia | Project Grant R01HL173869 | $370.8k | 9/18/24 |